Target intelligence / Profile preview

Calcineurin–Nuclear factor of activated T-cells docking interface (Cn–NFAT interface)

Target
Cn–NFAT interface
Molecular classification
Protein-protein interaction, Phosphatase-substrate interface
01

Overview

The Calcineurin–NFAT docking interface is a specialized protein-protein interaction site essential for the calcium-dependent signaling pathway that governs T-cell activation. Calcineurin, a serine/threonine phosphatase, recognizes and binds to the Nuclear Factor of Activated T-cells (NFAT) through two distinct conserved motifs: the high-affinity PxIxIT motif and the C-terminal LxVP motif (PubMed: 11430833, 17412991). Upon binding, calcineurin dephosphorylates multiple residues on NFAT, exposing its nuclear localization signal and allowing it to translocate into the nucleus to initiate the transcription of pro-inflammatory cytokines like IL-2 (UniProt: P17544). While classic inhibitors like Cyclosporine A and Tacrolimus effectively block this pathway by forming complexes that sterically hinder the active site, they often lead to off-target toxicity because they inhibit calcineurin's phosphatase activity toward all substrates (PubMed: 19144315). Modern therapeutic strategies focus on small molecules or peptides, such as the VIVIT peptide, that specifically compete for the docking interface to selectively inhibit NFAT activation without disrupting other vital calcineurin-mediated processes (PubMed: 11430833). This interface represents a high-value target for developing more precise immunosuppressive and anti-inflammatory agents with reduced side-effect profiles.

Other names
Cn–NFAT interaction sitePxIxIT docking siteLxVP docking siteCalcineurin-NFAT signaling axis
02

Mechanism of action

Inhibition of protein-protein interaction between calcineurin and NFAT, preventing NFAT dephosphorylation and subsequent nuclear translocation.

03

Biological functions

Signal transductionImmune responseT-cell activationGene expression regulationCell differentiation
04

Disease associations

Autoimmune diseaseOrgan transplant rejectionInflammationCardiac hypertrophyCancer
05

Safety considerations

Systemic immunosuppressionNephrotoxicity (associated with traditional calcineurin inhibitors)NeurotoxicityIncreased risk of opportunistic infections
06

Interacting drugs

Cyclosporine A

3 more in the full profile.

07

Biomarkers

NFAT nuclear translocation levelsInterleukin-2 (IL-2) expressionNFAT phosphorylation status

Beyond the preview

Go deeper on Calcineurin–Nuclear factor of activated T-cells docking interface (Cn–NFAT interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcineurin–Nuclear factor of activated T-cells docking interface (Cn–NFAT interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call